ENOVA host institutions

Here you find a short description of laboratories accepting candidates for short-term scientific missions. For more information about applications look here

Mentor and Host Institution

Techniques in the lab

Dr Maira Aguiar (mafsantos@fc.ul.pt)

NOVA University of Lisbon, Portugal

Basic and Advanced courses in Modeling and Data analysis.  Dr Aguiar works on statistical and mathematical problems applied to infectious disease transmission and control. (4-8 weeks)

Dr Zarko Barjaktarovic (Zarko.Barjaktarovic@calims.me)

Agency for Medicines and Medical Devices, Montenegro

Quality of Biologics - scientific and regulatory aspects. Systems biology approaches for analyses of complex data.  Dr Barjaktarovic works on systems biology analysis and is interested in "systems vaccinology". He is also working as Quality Assessor for Biologics including Advanced Therapy Medicinal Products. (1 week)

Dr Emiliano Bedini (ebedini@unina.it)

University of Napoli Federico II, Italy

Learn how to perform chemical reactions for the fine, tailored modification of MPLA structure and how to characterize the obtained derivatives by standard and advanced spectroscopic and spectrometric techniques (MALDI and ESI mass spectrometry, 1D- and 2D-NMR spectroscopy). (up to 90 days)

Dr Rita Berisio (rita.berisio@cnr.it)

Institute of Biostructures and Bioimaging, Italy

Structural biology and biochemistry, molecular biology, x-ray crystallography, CD and fluorescence spectroscopies, light scattering.  Dr Berisio works on structural biology of molecular systems involved in human infectious diseases, of vaccine candidates and adjuvants. (30-40 days)

Dr Olesja Bondarenko (olesja.bondarenko@kbfi.ee)

National Institute of Chemical Physics and Biophysics, Estonia

Interactions of immune cells with biomedical relevant nanomaterial (NM).  Dr Bondarenko is interested in the potential of NMs to act as vaccine adjuvants by potentiating the response of immune cells. STSM candidate needs to be approved by Dr Bondarenko’s institution (on the basis of CV, experience and recommendation letter). (up to 90 days)

Dr Dennis Christensen (den@ssi.dk)

Statens Serum institute, Denmark

Vaccine formulation and immunological studies.  Dr Christensen works on novel vaccine adjuvants and is co-inventor of the CAF01 and CAF09b adjuvants currently in human clinical trials. He is interested in both human and veterinary vaccines and prophylactic as well as therapeutic approaches. (up to 90 days)

Dr Nicolas Collin (nicolas.collin@unil.ch)

University of Lausanne, Switzerland

Formulation and characterization of adjuvanted vaccines.  Dr Collin is head of the Vaccine Formulation Laboratory, which acts as platform for adjuvants, providing access to a wide range of adjuvants and vaccine formulation expertise. Scope of STSM should be discussed prior application. (up to 90 days)

Prof Peter Delputte (peter.delputte@uantwerpen.be)

University of Antwerp, Belgium

Evaluation of RSV vaccines.  Prof Delputte is focusing on basic and applied research in infectious diseases (viruses, bacteria, parasites and fungi). (up to 90 days)

Dr Sandra Diebold (sandra.diebold@nibsc.org)

NIBSC, United Kingdom

Batch-release work associated with vaccines such as pyrogen testing; generation of reference materials.  Dr Diebold works on exploring nucleic acid Toll-like receptor agonist as adjuvants for tumor immunotherapy. (30-90 days)

Dr Alexandre Dobly (alexandre.dobly@sciensano.be)

Dr Lieke Van der Aa (Lieke.VanderAa@sciensano.be)

Sciensano, Belgium

The service "Quality of vaccines and blood products" at Sciensano is an Official Medicines Control Laboratory (OMCL) for biological medicinal products for human and veterinary use. Depending on the candidate's interest, the service may provide training in regulatory affairs, analytical development and validation. The service "Immune Response" at Sciensano, under the mentorship of Dr. Marta Romano, may organize training (theoretical and practical) on the screening of innate responses induced by novel adjuvants (analysis of PAMPs/PRRs interactions, inflammasome activation) using in vitro models. (5-10 days). Sciensano may host one or more STSM candidates during the third grant period.

Dr Mert Doskaya (mert.doskaya@ege.edu.tr)

Ege University Medical School, Turkey

Adjuvanted DNA vaccine and recombinant protein vaccine development.  Dr Doskaya works on vaccination studies in mouse model against infectious diseases (Toxoplasma gondii, Leishmania, FMDV) and breast cancer. He also works on Vaccine antigen discovery using protein microarrays. (up to 90 days)

Dr Ana Falcón (afalcon@cnb.csic.es)

National Center for Biotechnology (CNB), National Research Council, Spain

Evaluation of improved or new vaccine candidates or adjuvants in in vivo model (mice). Evaluation of innate immune response in cell culture.  Dr Falcon is virologist and focuses on pathogenicity factors of influenza virus. (up to 90 days from 2019)

Dr Pavol Farkas (chempalo@savba.sk)

Slovak Academy of Sciences, Slovakia

Preparation and characterization of carbohydrate-protein conjugates, fluorescent labeling and/or some immunological methods. Depending on the need of the candidate, it is possible to work in more depth on some specific methods.  Dr Farkas works on glycoconjugates as potential vaccine candidates and its testing in vivo and in vitro. (7-28 days)

Prof Alberto Fernández-Tejada (afernandeztejada@cicbiogune.es)

Center for Cooperative Research in Biosciences, Spain

Design, chemical synthesis and immunological evaluation of novel adjuvant molecules.  Prof Fernandez-Tejada works on the development of synthetic saponin-based adjuvants and molecular vaccines. (up to 90 days)

Prof Sveinbjorn Gizurarson (sveinbj@hi.is)

University of Iceland, Iceland

Short practical projects, preferably small MS or a part of a PhD project, where the student can carry out a small study in our laboratory.  Prof Gizurarson works in the field of mucosal adjuvants and mucosal vaccinations, with a special focus on understanding how formulation and adjuvants can be used to direct the immune response towards Th2 or Th1 (or Th3) responses. (up to 90 days)

Prof Tor Gjøen (tor.gjoen@farmasi.uio.no)

University of Oslo, Norway

In vitro testing of innate immune responses, transcriptomics.  The main topic of Prof Gjoen’s work is to understand innate immunity better to aid development of better adjuvants for vaccines in aquaculture, with emphasis on viral disease in salmon fish. (30 -60 days)

Dr Maya Guncheva (maiag@orgchm.bas.bg)

Institute of Organic Chemistry with Centre of Phytochemistry, Bulgaria

Training of work on a particular task.  Dr Maya Guncheva works on chemical modification of hemocyanins for obtaining new breast cancer and melanoma cancer vaccines. (30-45 days)

Prof Ihsan Gursel (ihsangursel@bilkent.edu.tr)

Bilkent University, Turkey

Any adjuvant related training can be offered.  Prof Gursel works on molecular and cellular mechanisms of innate sensors and adjuvant innovation as well as development of delivery vehicles for vaccine formulations. (up to 30 days)

Dr Maria Issagouliantis (maria.issagouliantis@rsu.lv)

Riga Stradins University, Latvia

Delivery of immunogens, DNA immunization, tumor protection experiments (after June 2018), in vivo imaging.  Dr Issagouliantis works on naked DNA vaccines against viruses causing chronic human infections, as HIV, HCV, HPV. (6 weeks)

Prof Ziga Jakopin (Ziga.Jakopin@ffa.uni-lj.si)

University of Ljubljana, Slovenia           

Evaluation of a compound library for their NOD1/NOD2/NLRP3 activation capacity; preliminary in vitro/ex vivo immunomodulatory activity (using cell lines, primary cells). (up to 90 days)

Prof Lana Kandalaft (lana.kandalaft@chuv.ch)

Centre hospitalier universitaire vaudois, Switzerland

Vaccine development.  Prof Kandalaft is working on DC vaccines in the clinic and in mouse models. (up to 90 days)

Prof Danina Krajisnik (danina@pharmacy.bg.ac.rs)

University of Belgrade, Serbia

Techniques of modified silica based materials preparation and characterization e.g. rheological measurements, zeta potential and particle size measurement, thermal analysis, light microscopy and analytical characterization.  Prof Krajisnik works on the pharmaceutical application of various natural and modified silica based materials. (30 days)

Prof Ed Lavelle (lavellee@tcd.ie)

Trinity College Dublin, Ireland

Training in culture and activation of dendritic cells and macrophages and roles of specific signaling pathways.  Prof Lavelle works on the mechanism of adjuvant action, innate immunity, and mucosal vaccines. (30-60 days)

Prof Georg Lipps (georg.lipps@fhnw.ch)

University of Applied Sciences and Arts Northwestern Switzerland (FHNW), Switzerland

Outer membrane vesicles (OMV), protein expression, antigen characterization.  Prof Lipps works on OMVs from gram-negative bacteria, which carry PAMPs that might be suitable as adjuvant. (60 days)

Dr Dragomira Majhen (dmajhen@irb.hr)

Ruder Boskovic Institute, Croatia

Cell and virus culture, virus research, confocal microscopy, standard methods used in molecular and cell biology.  Dr Majhen works on adenovirus-based vectors aimed at gene transfer and vaccination. (up to 90 days)

Dr Jose M. Martinez-Costas (jose.martinez.costas@usc.es)

University of Santiago de Compostela, Spain

Design, production and purification of microspheres containing antigens for vaccination.  Dr Martinez-Costas works on the molecular biology of avian reoviruses and on viral muNS protein, responsible for the construction of cytoplasmic viroplasms, for generating low-cost subunit vaccines. (2 weeks - 90 days)

Dr Siobhán McClean (siobhan.mcclean@ucd.ie)

University College Dublin, Ireland

Proteomic approaches for identification of bacterial proteins involved in host cell adhesion/ activation.  Dr McClean works on host-pathogen interactions and identification of vaccine antigens to prevent against Gram-negative pathogens. (28-42 days)

Prof Jela Milic (jela@pharmacy.bg.ac.rs)

University of Belgrade, Serbia

Rheological measurements, dynamic light scattering (zeta potential and particle size measurements), thermal analysis, light microscopy, biopharmaceutical and physicochemical characterization.  Prof Milic has experience in vehicles and colloidal carriers, which are or may be vaccines adjuvants/stabilizers, such as: different types of colloidal dispersions, microparticles, and liposomes. (30 days)

Dr Anita Milicic (anita.milicic@ndm.ox.ac.uk)

University of Oxford, United Kingdom

Vaccine design and production for pre-clinical studies (viral vectors and VLPs). Pre-clinical vaccine development (mouse models), evaluating immunogenicity and vaccine efficacy for an array of infectious diseases, and prostate cancer. Vaccine encapsulation technologies for single-dose immunisation. Introduction to vaccine clinical trials, Phase I or Phase II (challenge) using adjuvanted or virus-vectored vaccines. The candidate would also attend relevant University and Institute seminars. (1-3 weeks)

Prof Antonio Molinaro (molinaro@unina.it)

University of Napoli Federico II, Italy

Scientific training/work in the lab.  Prof Antonio Molinaro works on Glycolipid based Adjuvants. (30-90 days)

Prof Cristina Nativi (cristina.nativi@unifi.it)

University of Florence, Italy

Glycoconjugation (antigens to carriers/adjuvants).  Prof Nativi works in the development of synthetic cancer vaccines. (2-3 month)

Dr Ivana Pantelic (ivana.pantelic@pharmacy.bg.ac.rs)

Dr Snezana Savic (snexs@pharmacy.bg.ac.rs)

University of Belgrade, Serbia

Techniques of nano-dispersed systems preparation, rheological measurements, dynamic light scattering (zeta potential and particle size measurements), thermal analysis (DSC, FTIR), light microscopy, atomic force microscopy (AFM on demand), biopharmaceutical and analytical characterization (e.g. UPLC-MS/MS).  Dr Pantelic and Dr Savic work on colloidal drug delivery systems that could also serve as vaccine adjuvants. (30 days)

Prof Jacob Pitcovski (jp@migal.org.il)

MIGAL, Israel

Cloning, expression, immunological tests.  Prof Pitcovski works in vaccine development and is interested in biological adjuvants, e.g. LT of E.COLI and innate immunity inducers. (7-14 days)

Dr Ehud Shahar (ehudsha@migal.org.il)

MIGAL, Israel

Open to ideas.  Dr Shahar work is focused on targeted activation of the innate immune response by using combinations of inducer molecules bound to microparticles. He is interested in finding the optimal inducer combination to induce a tumor hostile microenvironment. (up to 90 days)

Prof Artur Summerfield (artur.summerfield@vetsuisse.unibe.ch)

University of Bern, Switzerland

Laboratory work.  Prof Summerfield works on improving veterinary adjuvants for duration of immunity, on mucosal vaccines, and system immunology approaches to adjuvant research. (up to 90 days)

Dr Maria Vono (Maria.Vono@unige.ch)

University of Geneva, Switzerland

Methods to characterize innate and adaptive immune responses to vaccine formulations.  Dr Vono is interested in vaccine responses in early life, which faces additional challenges due to intrinsic limitations of the immune system in the very young. (5 days)

Dr Pierre Schembri (pierre.schembri-wismayer@um.edu.mt)

University of Malta, Malta

Making formalin fixed vaccines and/or trying out novel therapies with adjuvants on the MT-450 metastatic cancer model. (14-42 days)

Dr Martinus Capelle (mcapelle@its.jnj.com)

Janssen, Netherlands

Janssen Vaccines has regular internships and visiting PhD students as long as they can comply with the companies' confidentiality requirements. Hosting STSM candidates would still need to be confirmed after an internal Janssen review and approval process. In general, we encourage publication of scientific papers, open innovation models and look forward to collaborate with talent. (90 days)

Prof Louise Cosby (Louise.Cosby@afbini.gov.uk)

Agri-Food and Biosciences Institute, United Kingdom

From molecular biology around vaccine production through to animals models (including virology, bacteriology , immunology and pathology). We work closely with Queen's University Belfast (I am an emeritus professor there) so training can be joint. (up to 90 days)

   
Published Mar. 22, 2018 4:33 PM - Last modified June 27, 2018 11:03 AM